Is Sanofi on the Verge of Another Blockbuster?

The U.S. Food and Drug Administration (FDA) recently announced that it had accepted Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) supplemental Biologics License Application for priority review of Dupixent to treat patients with a rare skin disease called prurigo nodularis. 

With a decision from the FDA expected by the end of September, it's worth asking the following question: What would the annual sales potential be for Sanofi if Dupixent became the first drug in the U.S. to be specifically indicated to treat prurigo nodularis? To find out, let's take a look at the results from Dupixent's clinical trials for the potential indication and the condition's market size potential in the U.S. 

Prurigo nodularis is an inflammatory skin condition that is characterized by an intense, persistent itch. The disease can also come with thick patches of skin called nodules that can cover the majority of the body. 

Continue reading

Source Fool.com